gsk201410206k1.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending October 2014
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--




 Notification of Transactions of Directors, Persons Discharging
Managerial Responsibility or Connected Persons
 
 
I give below details of the following increase in interests in American Depositary Shares (ADSs) of GlaxoSmithKline plc purchased at a price of $45.253 per ADS on 8 October 2014, in respect of the personal holding of the under-mentioned Connected Person following the re-investment of the dividend paid to shareholders on 2 October 2014.
 
 
 
 
Director/PDMR
 
 
 
Connected Person
 
Number of ADS
 
Dr M M Slaoui
 
 
Dr K Slaoui
 
37.405
 
 
The Company was advised of this information on 17 October 2014.
 
This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
 
 
V A Whyte
Company Secretary
 
20 October 2014
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: October 20, 2014 
 
 
By: VICTORIA WHYTE
----------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc